Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Neoplasia. 2010 Dec; 12(12): 957–968.
PMCID: PMC3003131
PMID: 21170260

Dinosaurs and Ancient Civilizations: Reflections on the Treatment of Cancer

Abstract

Research efforts in the area of palaeopathology have been seen as an avenue to improve our understanding of the pathogenesis of cancer. Answers to questions of whether dinosaurs had cancer, or if cancer plagued ancient civilizations, have captured the imagination as well as the popular media. Evidence for dinosaurian cancer may indicate that cancer may have been with us from the dawn of time. Ancient recorded history suggests that past civilizations attempted to fight cancer with a variety of interventions. When contemplating the issuewhy a generalized cure for cancer has not been found, it might prove useful to reflect on the relatively limited timethat this issue has been an agenda item of governmental attention as well as continued introduction of an every evolving myriad of manmade carcinogens relative to the total time cancer has been present on planet Earth. This article reflects on the history of cancer and the progress made following the initiation of the “era of cancer chemotherapy.”

Perspective

Evidence from Dinosaurs (250 to 65 Million Years Ago)

Unraveling the history of cancer may provide insights and improve our understanding of the etiology, pathogenesis, and intervention of this disease. While it had been thought that there was generally ample evidence that cancer was a normal population phenomenon in dinosaurs, doubts still lingered as conclusive evidence was lacking. Earth history is divided into aeons, eras, and periods. Dinosaurs and other prehistoric reptiles roamed the Earth during the Mesozoic era for about 185 million years, which lasted from 250 to 65 million years ago. This era contained three periods called the Triassic, Jurassic, and Cretaceous.

Recently, metastatic cancer and osteomas (in mosasaurs) were reported (Rothschild BM, Witzke BJ, and Hershkovitz I [1999]. Metastatic cancer in the Jurassic. Lancet 354 (9176), 398.). Even more recently, researchers undertook an epidemiological investigation of tumors in dinosaurs (Rothschild BM, Tanke DH, Helbling M 2nd, and Martin LD [2003]. Epidemiologic study of tumors in dinosaurs. Naturwissenschaften 90 (11), 495–500). These investigators used computed tomography for fluoroscopically screeningmore than 10,000 specimens of dinosaur vertebrae for evidence of tumors. Of the specimens examined, investigators reported tumors in bones of Cretaceous hadrosaurs (duck-billed dinosaurs). In this species, maximum cancer susceptibility was approximately 3% of bones examined, which showed lumps by imaging identified as various types of tumors including hemangiomas, metastatic cancer, desmoplastic fibroma, and osteoblastoma. The familial pattern found seemed to reflect a genetic propensity or, alternatively, the result of environmental mutagens because these dinosaurs likely ate foliage of conifers rich in carcinogenic tannins, phenols, and resins.

Taking into account the limitations of the diagnostic tools used to study remains, there is an agreement that cancer in dinosaurs is relatively scarce. Age at death, diet, and environmental factors may have a significant influence on the incidence of these cancers.

Evidence from Ancient Civilizations (Egyptian, Greek, and Roman)

A recent overview of the literature investigating the presence of cancer in ancient civilizations has been published (David AR and Zimmerman MR [2010]. Cancer: an old disease, a new disease or something in between? Nat Rev Cancer 10, 728–733). Evidence of cancer in humans has been uncovered in the earliest medical records found left by the ancient Egyptians (3000–800 bc). Evidence consists of hieroglyphic inscriptions along with papyri writings noting both benign and malignant tumors. Egyptian culture allowed for working with human bodies as evidenced by the mummification of the dead. The first histological confirmation of cancer in an Egyptian mummy revealed that cancer was indeed present in ancient times (Zimmerman MR [1977]. An experimental study of mummification pertinent to the antiquity of cancer. Cancer 40, 1358–1362). In this report, Zimmerman diagnosed the presence of rectal cancer in an unnamed mummy who had lived in the Dakhleh Oasis during the Ptolemaic period (ce 200–400). The fact that palaeopathology has shown that cancer is present in ancient remains of Egyptians necessitated the need for the ancients to counter attack this disease. Deciphered papyri from around 1500 bc contain descriptions of cancer along with surgical intervention and treatments. Evidence for the use of surgical removal of superficial tumors has been found during this time. Deep-seated tumors were treated using different prescriptions including ears of pigs and other parts of animals and fish in such dispensions as poultices, ointments, and enemas. Thus, ancient Egyptian physicians treated patients for several forms of cancer, and their documents have provided both evidence of the disease along with the treatments administered at the time. Egyptians were considered the “fathers of pharmacology” as some treatments used were believed to be “magical” but were, in fact, true therapeutic remedies.

An interesting phenomenon has arisen during the course of multi-year studies related to the rarity of cancer in antiquity. This is of interest especially when considering that hundreds of Egyptian mummies and more than 10,000 dinosaur bones were evaluated. In contrast, the rate of cancer incidence has dramatically increased since the Industrial Revolution. The rarity of cancer in antiquity has been attributed to the lack of pollution and changes in diet and lifestyle, and most recent findings suggest that cancer may be a manmade disease (Nat Rev Cancer 10, 728–733). Thus, while a lack of adequate techniques for disease diagnosis and detection may partially explain the overall lack of cancer found during the millennia, the current cancer trends are now primarily associated with carcinogens in our modern industrialized society (Nat Rev Cancer 10, 728–733). Whether this hypothesis is indeed the case, what is clear from ancient Egyptian and Greek writings along with information accumulated throughout the millennia is that improved understanding of the biological basis for the disease as well as improved cancer treatments is needed.

Overall Cancer Perspective

To put the historical findings into a more modern perspective, in more than 3500 years of attempting to treat cancers effectively, the concept of cancer chemotherapy was initiated only relatively recently in the 1940s with the introduction of nitrogen mustards and folic acid. These initial discoveries using poisonous chemicals for the treatment of tumors were a major medical advance as progress rapidly ensued, leading to improvements in many cancer death rates. Moreover, the potential and realities of targeted anticancer therapies have more recently emerged some 50 to 70 years later. However, much work remains as cancer continues to be a major worldwide health problem, and progress in curing patients with metastatic cancer remains elusive.

In an effort to continue to advance treatments against cancers, Neoplasia continues to serve as a major conduit for the dissemination of relevant and timely information. Neoplasia has published numerous significant articles covering broad areas of research including cell and tumor biology, imaging, genetics, experimental therapeutics, and clinical investigations (Table 1). Neoplasia provides its readership with a broad scope related to many novel and diverse discoveries. The immediate availability of Neoplasia articles to the worldwide clinical cancer research community is a key and unique feature of Neoplasia, and our primary goal is to allow open access of all articles at the time of publication through Pub ed Central. This feature provides authors' research findings to the largest possible readership, thereby ensuring that articles published in Neoplasia will have the opportunity to make a significant impact. Finally, it has been a pleasure to serve the cancer research community as editor this past year, and along with my editorial board, I thank the scientific groups who have published with us and take this as the highest form of honor.

Table 1

Summary of Published Articles.

Subject200820092010
Cancer genetics[1,3,7,2326,30,46,54,61,64,65,69,72,76,89,90,102,107,113,117,120,122,125,128,136,140,146][154,159,168,171,182,193,218,225,230,250,256,262,265,280282][289,302304,308,310,315,326,327,336,357,374,381,387]
Cell and tumor biology[2,9,10,1419,27,28,32,39,42,47,49,51,53,56,57,59,60,68,73,75,77,78,81,82,84,88,91,96,97,99,101,106,112,114,115,119,121,123,124,126,127,131134,137139,143145,150][153,158,161,164,167,170,172,174,177,179181,183,185,186,188,189,191,192,198,200202,204,207,209,210,212,213,215,217,220,223,226,229,231-234,236238,242,244,246,247,249,252,253,260,268,270,271,273,277,279,283,285][290,292,293,298300,306,311313,316,318,321,322,329,331,332,335,337,339,340,342,344346,348,351,352,354,355,358,361,363,365367,369373,376378,384,385,388,390,391]
Experimental therapeutics[46,21,22,29,34,35,43,48,50,63,66,70,74,79,80,85,9295,103,109,110,129,135,148,151][155,160,162,166,187,199,206,211,222,224,240,255,261,264,269,284,286][287,291,294,295,317,324,333,338,341,350,360,362,379,382,389]
Tumor immunology[11,33,45,87,98,100,111][216,245,248,258,276][309,320,323,325,364]
Epidemiology and prevention[37,41,83,118][152,173,178,195,196,208,221,227,228,254,257,266,267,272,274][297,386]
Cancer imaging[20,31,36,40,44,52,71,104,108,149][156,157,163,175,176,184,197,205,235,239,241,251,278][301,347,356,368]
Clinical investigations[8,13,55,62,67,105,116][190][296,305,307,343,349,353,380]
Animal models[12,38,58,86,130,141,142,147][165,169,194,203,214,219,243,259,263,275][288,314,319,328,330,334,359,375,383]

References

1. Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 2008;10:1–7. [PMC free article] [PubMed] [Google Scholar]
2. Crissey MA, Guo RJ, Fogt F, Li H, Katz JP, Silberg DG, Suh ER, Lynch JP. The homeodomain transcription factor Cdx1 does not behave as an oncogene in normal mouse intestine. Neoplasia. 2008;10:8–19. [PMC free article] [PubMed] [Google Scholar]
3. Tam NN, Szeto CY, Sartor MA, Medvedovic M, Ho SM. Gene expression profiling identifies lobe-specific and common disruptions of multiple gene networks in testosterone-supported, 17β-estradiol- or diethylstilbestrol-induced prostate dysplasia in Noble rats. Neoplasia. 2008;10:20–40. [PMC free article] [PubMed] [Google Scholar]
4. Cai J, Niu X, Chen Y, Hu Q, Shi G, Wu H, Wang J, Yi J. Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia. 2008;10:41–51. [PMC free article] [PubMed] [Google Scholar]
5. Yeh HH, Wu CH, Giri R, Kato K, Kohno K, Izumi H, Chou CY, Su WC, Liu HS. Oncogenic Ras-induced morphologic change is through MEK/ERK signaling pathway to downregulate Stat3 at a posttranslational level in NIH3T3 cells. Neoplasia. 2008;10:52–60. [PMC free article] [PubMed] [Google Scholar]
6. Rodrigues EG, Dobroff AS, Cavarsan CF, Paschoalin T, Nimrichter L, Mortara RA, Santos EL, Fazio MA, Miranda A, Daffre S, et al. Effective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesin. Neoplasia. 2008;10:61–68. [PMC free article] [PubMed] [Google Scholar]
7. Kim MK, Mason JM, Li CM, Berkofsky-Fessler W, Jiang L, Choubey D, Grundy PE, Tycko B, Licht JD. A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16. Neoplasia. 2008;10:69–78. [PMC free article] [PubMed] [Google Scholar]
8. Yu J, Yu J, Cordero KE, Johnson MD, Ghosh D, Rae JM, Chinnaiyan AM, Lippman ME. A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia. 2008;10:79–88. [PMC free article] [PubMed] [Google Scholar]
9. De Smaele E, Fragomeli C, Ferretti E, Pelloni M, Po A, Canettieri G, Coni S, Di Marcotullio L, Greco A, Moretti M, et al. An integrated approach identifies Nhlh1 and Insm1 as Sonic Hedgehog-regulated genes in developing cerebellum and medulloblastoma. Neoplasia. 2008;10:89–98. [PMC free article] [PubMed] [Google Scholar]
10. Vojtechova M, Tureckova J, Kucerova D, Sloncova E, Vachtenheim J, Tuhackova Z. Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia. 2008;10:99–107. [PMC free article] [PubMed] [Google Scholar]
11. Banciu M, Metselaar JM, Schiffelers RM, Storm G. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia. 2008;10:108–117. [PMC free article] [PubMed] [Google Scholar]
12. Huang S, Chen Y, Podsypanina K, Li Y. Comparison of expression profiles of metastatic versus primary mammary tumors in MMTV-Wnt-1 and MMTV-Neu transgenic mice. Neoplasia. 2008;10:118–124. [PMC free article] [PubMed] [Google Scholar]
13. Shafat I, Pode D, Peretz T, Ilan N, Vlodavsky I, Nisman B. Clinical significance of urine heparanase in bladder cancer progression. Neoplasia. 2008;10:125–130. [PMC free article] [PubMed] [Google Scholar]
14. Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, Spalding AC, Nor JE. Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia. 2008;10:131–139. [PMC free article] [PubMed] [Google Scholar]
15. Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, Ignatenko NA. Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells. Neoplasia. 2008;10:140–148. [PMC free article] [PubMed] [Google Scholar]
16. Hwang JH, Smith CA, Salhia B, Rutka JT. The role of fascin in the migration and invasiveness of malignant glioma cells. Neoplasia. 2008;10:149–159. [PMC free article] [PubMed] [Google Scholar]
17. Yan M, Shen J, Person MD, Kuang X, Lynn WS, Atlas D, Wong PK. Endoplasmic reticulum stress and unfolded protein response in Atm-deficient thymocytes and thymic lymphoma cells are attributable to oxidative stress. Neoplasia. 2008;10:160–167. [PMC free article] [PubMed] [Google Scholar]
18. Rosenow F, Ossig R, Thormeyer D, Gasmann P, Schluter K, Brunner G, Haier J, Eble JA. Integrins as antimetastatic targets of RGD-independent snake venom components in liver metastasis [corrected] Neoplasia. 2008;10:168–176. [PMC free article] [PubMed] [Google Scholar]
19. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008;10:177–188. [PMC free article] [PubMed] [Google Scholar]
20. Lefranc F, Kiss R. The sodium pump a1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia. 2008;10:198–206. [PMC free article] [PubMed] [Google Scholar]
21. Foster PJ, Dunn EA, Karl KE, Snir JA, Nycz CM, Harvey AJ, Pettis RJ. Cellular magnetic resonance imaging: in vivo imaging of melanoma cells in lymph nodes of mice. Neoplasia. 2008;10:207–216. [PMC free article] [PubMed] [Google Scholar]
22. Craig DH, Downey C, Basson MD. SiRNA-mediated reduction of α-actinin-1 inhibits pressure-induced murine tumor cell wound implantation and enhances tumor-free survival. Neoplasia. 2008;10:217–222. [PMC free article] [PubMed] [Google Scholar]
23. Spankuch B, Steinhauser I, Wartlick H, Kurunci-Csacsko E, Strebhardt KI, Langer K. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia. 2008;10:223–234. [PMC free article] [PubMed] [Google Scholar]
24. Jiang W, Cazacu S, Xiang C, Zenklusen JC, Fine HA, Berens M, Armstrong B, Brodie C, Mikkelsen T. FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-κB signaling pathway. Neoplasia. 2008;10:235–243. [PMC free article] [PubMed] [Google Scholar]
25. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA. CXCL5 promotes prostate cancer progression. Neoplasia. 2008;10:244–254. [PMC free article] [PubMed] [Google Scholar]
26. Sasaki M, Sakano S, Okayama N, Akao J, Hara T, Kawai Y, Ohmi C, Hinoda Y, Naito K. DNArepair gene polymorphisms may be associated with prognosis of upper urinary tract transitional cell carcinoma. Neoplasia. 2008;10:255–265. [PMC free article] [PubMed] [Google Scholar]
27. Ateeq B, Unterberger A, Szyf M, Rabbani SA. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia. 2008;10:266–278. [PMC free article] [PubMed] [Google Scholar]
28. Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley EL, Siegert G. Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia. 2008;10:279–286. [PMC free article] [PubMed] [Google Scholar]
29. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX, Fang JY. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008;10:287–297. [PMC free article] [PubMed] [Google Scholar]
30. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10:298–302. [PMC free article] [PubMed] [Google Scholar]
31. Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, et al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia. 2008;10:303–313. [PMC free article] [PubMed] [Google Scholar]
32. Li Q, Mullins SR, Sloane BF, Mattingly RR. p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia. 2008;10:314–329. [PMC free article] [PubMed] [Google Scholar]
33. Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, Nozawa H, Lewis CE, Hanahan D. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia. 2008;10:329–340. [PMC free article] [PubMed] [Google Scholar]
34. van der Horst EH, Frank BT, Chinn L, Coxon A, Li S, Polesso F, Slavin A, Ruefli-Brasse A, Wesche H. The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo. Neoplasia. 2008;10:340–347. [PMC free article] [PubMed] [Google Scholar]
35. Gil Z, Kelly KJ, Brader P, Shah JP, Fong Y, Wong RJ. Utility of a herpes oncolytic virus for the detection of neural invasion by cancer. Neoplasia. 2008;10:347–353. [PMC free article] [PubMed] [Google Scholar]
36. Gaustad JV, Brurberg KG, Simonsen TG, Mollatt CS, Rofstad EK. Tumor vascularity assessed by magnetic resonance imaging and intravital microscopy imaging. Neoplasia. 2008;10:354–362. [PMC free article] [PubMed] [Google Scholar]
37. Coppola JM, Bhojani MS, Ross BD, Rehemtulla A. A small-molecule furin inhibitor inhibits cancer cellmotility and invasiveness. Neoplasia. 2008;10:363–370. [PMC free article] [PubMed] [Google Scholar]
38. Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, et al. An in vivo mouse model for human prostate cancer metastasis. Neoplasia. 2008;10:371–380. [PMC free article] [PubMed] [Google Scholar]
39. Mikhaylova M, Mori N, Wildes FB, Walczak P, Gimi B, Bhujwalla ZM. Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia. 2008;10:380–389. [PMC free article] [PubMed] [Google Scholar]
40. Li C, Greenwood TR, Glunde K. Glucosamine-bound near-infrared fluorescent probes with lysosomal specificity for breast tumor imaging. Neoplasia. 2008;10:389–398. [PMC free article] [PubMed] [Google Scholar]
41. Wang S, Liu H, Ren L, Pan Y, Zhang Y. Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia. 2008;10:399–407. [PMC free article] [PubMed] [Google Scholar]
42. Cruz-Monserrate Z, O'Connor KL. Integrin α6β4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation. Neoplasia. 2008;10:408–417. [PMC free article] [PubMed] [Google Scholar]
43. Lorenzo PI, Saatcioglu F. Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. Neoplasia. 2008;10:418–428. [PMC free article] [PubMed] [Google Scholar]
44. Mitra S, Foster TH. In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-l-aspartylchlorin-e6. Neoplasia. 2008;10:429–438. [PMC free article] [PubMed] [Google Scholar]
45. Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, Cher ML. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia. 2008;10:439–449. [PMC free article] [PubMed] [Google Scholar]
46. Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia. 2008;10:450–461. [PMC free article] [PubMed] [Google Scholar]
47. Sticht C, Freier K, Knopfle K, Flechtenmacher C, Pungs S, Hofele C, Hahn M, Joos S, Lichter P. Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC) Neoplasia. 2008;10:462–470. [PMC free article] [PubMed] [Google Scholar]
48. Al-Romaih K, Sadikovic B, Yoshimoto M, Wang Y, Zielenska M, Squire JA. Decitabine-induced demethylation of 5′ CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia. 2008;10:471–480. [PMC free article] [PubMed] [Google Scholar]
49. Giusti I, D'Ascenzo S, Millimaggi D, Taraboletti G, Carta G, Franceschini N, Pavan A, Dolo V. Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia. 2008;10:481–488. [PMC free article] [PubMed] [Google Scholar]
50. Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, Zigler M, Wang H, Bar-Eli M, Kerbel RS, et al. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia. 2008;10:489–500. [PMC free article] [PubMed] [Google Scholar]
51. Lyustikman Y, Momota H, Pao W, Holland EC. Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia. 2008;10:501–510. [PMC free article] [PubMed] [Google Scholar]
52. Bauerle T, Hilbig H, Bartling S, Kiessling F, Kersten A, Schmitt-Graff A, Kauczor HU, Delorme S, Berger MR. Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. Neoplasia. 2008;10:511–520. [PMC free article] [PubMed] [Google Scholar]
53. Golan M, Hizi A, Resau JH, Yaal-Hahoshen N, Reichman H, Keydar I, Tsarfaty I. Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. Neoplasia. 2008;10:521–533. [PMC free article] [PubMed] [Google Scholar]
54. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008;10:534–541. [PMC free article] [PubMed] [Google Scholar]
55. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia. 2008;10:542–548. [PMC free article] [PubMed] [Google Scholar]
56. Nazarenko I, Marhaba R, Reich E, Voronov E, Vitacolonna M, Hildebrand D, Elter E, Rajasagi M, Apte RN, Zoller M. Tumorigenicity of IL-1α- and IL-1β-deficient fibrosarcoma cells. Neoplasia. 2008;10:549–562. [PMC free article] [PubMed] [Google Scholar]
57. Gu P, Xing X, Tanzer M, Rocken C, Weichert W, Ivanauskas A, Pross M, Peitz U, Malfertheiner P, Schmid RM, et al. Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia. 2008;10:563–572. [PMC free article] [PubMed] [Google Scholar]
58. Mijatovic T, Mahieu T, Bruyere C, De Neve N, Dewelle J, Simon G, Dehoux MJ, van der Aar E, Haibe-Kains B, Bontempi G, et al. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia. 2008;10:573–586. [PMC free article] [PubMed] [Google Scholar]
59. Zuco V, Zunino F. Cyclic pifithrin-a sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. Neoplasia. 2008;10:587–596. [PMC free article] [PubMed] [Google Scholar]
60. Reddy RC, Srirangam A, Reddy K, Chen J, Gangireddy S, Kalemkerian GP, Standiford TJ, Keshamouni VG. Chemotherapeutic drugs induce PPAR-γ expression and show sequence-specific synergy with PPAR-γ ligands in inhibition of non-small cell lung cancer. Neoplasia. 2008;10:597–603. [PMC free article] [PubMed] [Google Scholar]
61. Baia GS, Stifani S, Kimura ET, McDermott MW, Pieper RO, Lal A. Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas. Neoplasia. 2008;10:604–612. [PMC free article] [PubMed] [Google Scholar]
62. Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, Ran S. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia. 2008;10:613–623. [PMC free article] [PubMed] [Google Scholar]
63. Rinnab L, Schutz SV, Diesch J, Schmid E, Kufer R, Hautmann RE, Spindler KD, Cronauer MV. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful? Neoplasia. 2008;10:624–634. [PMC free article] [PubMed] [Google Scholar]
64. Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, Fuessel S, Wuttig D, Wirth MP, Baretton GB. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density Affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia. 2008;10:634–642. [PMC free article] [PubMed] [Google Scholar]
65. Privette LM, Weier JF, Nguyen HN, Yu X, Petty EM. Loss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. Neoplasia. 2008;10:643–652. [PMC free article] [PubMed] [Google Scholar]
66. Siwko SK, Bu W, Gutierrez C, Lewis B, Jechlinger M, Schaffhausen B, Li Y. Lentivirus-mediated oncogene introduction into mammary cells in vivo induces tumors. Neoplasia. 2008;10:653–662. 651 p following 662. [PMC free article] [PubMed] [Google Scholar]
67. Missbach-Guentner J, Dullin C, Kimmina S, Zientkowska M, Domeyer-Missbach M, Malz C, Grabbe E, Stuhmer W, Alves F. Morphologic changes of mammary carcinomas in mice over time as monitored by flat-panel detector volume computed tomography. Neoplasia. 2008;10:663–673. [PMC free article] [PubMed] [Google Scholar]
68. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, et al. High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia. 2008;10:674–679. [PMC free article] [PubMed] [Google Scholar]
69. Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE, Dallapiccola B, Lothe RA. RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia. 2008;10:680–686. 682 p following 686. [PMC free article] [PubMed] [Google Scholar]
70. Koletsa T, Kostopoulos I, Charalambous E, Christoforidou B, Nenopoulou E, Kotoula V. A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia. 2008;10:687–696. [PMC free article] [PubMed] [Google Scholar]
71. Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, Oka M, Imai K, Dahiya R, Hinoda Y. Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia. 2008;10:697–705. [PMC free article] [PubMed] [Google Scholar]
72. Ruddell A, Harrell MI, Minoshima S, Maravilla KR, Iritani BM, White SW, Partridge SC. Dynamic contrast-enhanced magnetic resonance imaging of tumor-induced lymph flow. Neoplasia. 2008;10:706–713. 701 p following 713. [PMC free article] [PubMed] [Google Scholar]
73. Rambow F, Piton G, Bouet S, Leplat JJ, Baulande S, Marrau A, Stam M, Horak V, Vincent-Naulleau S. Gene expression signature for spontaneous cancer regression in melanoma pigs. Neoplasia. 2008;10:714–726. 711 p following 726. [PMC free article] [PubMed] [Google Scholar]
74. Brurberg KG, Gaustad JV, Mollatt CS, Rofstad EK. Temporal heterogeneity in blood supply in human tumor xenografts. Neoplasia. 2008;10:727–735. [PMC free article] [PubMed] [Google Scholar]
75. Yu LJ, Wu ML, Li H, Chen XY, Wang Q, Sun Y, Kong QY, Liu J. Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells. Neoplasia. 2008;10:736–744. [PMC free article] [PubMed] [Google Scholar]
76. Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia. 2008;10:745–756. [PMC free article] [PubMed] [Google Scholar]
77. Potter N, Karakoula A, Phipps KP, Harkness W, Hayward R, Thompson DN, Jacques TS, Harding B, Thomas DG, Palmer RW, et al. Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma. Neoplasia. 2008;10:757–772. [PMC free article] [PubMed] [Google Scholar]
78. Mellone M, Rinaldi C, Massimi I, Petroni M, Veschi V, Talora C, Truffa S, Stabile H, Frati L, Screpanti I, et al. Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis. Neoplasia. 2008;10:773–781. [PMC free article] [PubMed] [Google Scholar]
79. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, Fischer SM. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia. 2008;10:782–796. [PMC free article] [PubMed] [Google Scholar]
80. Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, van Golen KL. Type I collagen receptor (α2β1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia. 2008;10:797–803. [PMC free article] [PubMed] [Google Scholar]
81. Levkoff LH, Marshall GP, II, Ross HH, Caldeira M, Reynolds BA, Cakiroglu M, Mariani CL, Streit WJ, Laywell ED. Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo. Neoplasia. 2008;10:804–816. [PMC free article] [PubMed] [Google Scholar]
82. Nevo I, Sagi-Assif O, Edry Botzer L, Amar D, Maman S, Kariv N, Leider-Trejo LE, Savelyeva L, Schwab M, Yron I, et al. Generation and characterization of novel local and metastatic human neuroblastoma variants. Neoplasia. 2008;10:816–827. [PMC free article] [PubMed] [Google Scholar]
83. Liu X, Shi Y, Woods KW, Hessler P, Kroeger P, Wilsbacher J, Wang J, Wang JY, Li C, Li Q, et al. Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia. 2008;10:828–837. [PMC free article] [PubMed] [Google Scholar]
84. Williams PD, Lee JK, Theodorescu D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia. 2008;10:838–846. [PMC free article] [PubMed] [Google Scholar]
85. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia. 2008;10:847–856. [PMC free article] [PubMed] [Google Scholar]
86. Bhattacharya A, Toth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum YM. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. Neoplasia. 2008;10:857–865. [PMC free article] [PubMed] [Google Scholar]
87. Hollander MC, Balogh AR, Liwanag J, Han W, Linnoila RI, Anver MR, Dennis PA. Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. Neoplasia. 2008;10:866–872. [PMC free article] [PubMed] [Google Scholar]
88. Hetschko H, Voss V, Senft C, Seifert V, Prehn JH, Kogel D. BH3 mimetics reactivate autophagic cell death in anoxia-resistant malignant glioma cells. Neoplasia. 2008;10:873–885. [PMC free article] [PubMed] [Google Scholar]
89. Isenberg JS, Hyodo F, Ridnour LA, Shannon CS, Wink DA, Krishna MC, Roberts DD. Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia. 2008;10:886–896. [PMC free article] [PubMed] [Google Scholar]
90. Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Ewing CM, Dalrymple S, Turner AR, Sun J, et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia. 2008;10:897–907. [PMC free article] [PubMed] [Google Scholar]
91. Chan MW, Huang YW, Hartman-Frey C, Kuo CT, Deatherage D, Qin H, Cheng AS, Yan PS, Davuluri RV, Huang TH, et al. Aberrant transforming growth factor β1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia. 2008;10:908–919. [PMC free article] [PubMed] [Google Scholar]
92. Bonte D, Lindvall C, Liu H, Dykema K, Furge K, Weinreich M. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia. 2008;10:920–931. [PMC free article] [PubMed] [Google Scholar]
93. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia. 2008;10:932–939. [PMC free article] [PubMed] [Google Scholar]
94. Genin O, Rechavi G, Nagler A, Ben-Itzhak O, Nazemi KJ, Pines M. Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment? Neoplasia. 2008;10:940–948. [PMC free article] [PubMed] [Google Scholar]
95. El Sheikh SS, Romanska HM, Abel P, Domin J, Lalani el-N. Predictive value of PTENand ARcoexpression of sustained responsiveness to hormonal therapy in prostate cancer—a pilot study. Neoplasia. 2008;10:949–953. [PMC free article] [PubMed] [Google Scholar]
96. Scheper MA, Shirtliff ME, Meiller TF, Peters BM, Jabra-Rizk MA. Farnesol, a fungal quorum-sensing molecule triggers apoptosis in human oral squamous carcinoma cells. Neoplasia. 2008;10:954–963. [PMC free article] [PubMed] [Google Scholar]
97. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancer. Neoplasia. 2008;10:964–972. [PMC free article] [PubMed] [Google Scholar]
98. Grochola LF, Greither T, Taubert HW, Moller P, Knippschild U, Udelnow A, Henne-Bruns D, Wurl P. Prognostic relevance of hTERT mRNA expression in ductal adenocarcinoma of the pancreas. Neoplasia. 2008;10:973–976. [PMC free article] [PubMed] [Google Scholar]
99. Chen T, Tang XD, Wan Y, Chen L, Yu ST, Xiong Z, Fang DC, Liang GP, Yang SM. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia. 2008;10:977–986. [PMC free article] [PubMed] [Google Scholar]
100. Ryzhov S, Novitskiy SV, Zaynagetdinov R, Goldstein AE, Carbone DP, Biaggioni I, Dikov MM, Feoktistov I. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia. 2008;10:987–995. [PMC free article] [PubMed] [Google Scholar]
101. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thuroff JW, Vessella RL, Cher ML, et al. C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia. 2008;10:996–1003. [PMC free article] [PubMed] [Google Scholar]
102. Liu B, Yu HM, Huang J, Hsu W. Co-opted JNK/SAPK signaling in Wnt/β-catenin-induced tumorigenesis. Neoplasia. 2008;10:1004–1013. [PMC free article] [PubMed] [Google Scholar]
103. Kischel P, Guillonneau F, Dumont B, Bellahcene A, Stresing V, Clezardin P, De Pauw EA, Castronovo V. Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia. 2008;10:1014–1020. [PMC free article] [PubMed] [Google Scholar]
104. Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, Kobel M. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008;10:1021–1027. [PMC free article] [PubMed] [Google Scholar]
105. Zhu Q, Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman SH. Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia. 2008;10:1028–1040. [PMC free article] [PubMed] [Google Scholar]
106. de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drugsensitive tumor, testicular cancer. Neoplasia. 2008;10:1041–1048. [PMC free article] [PubMed] [Google Scholar]
107. Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia. 2008;10:1049–1056. [PMC free article] [PubMed] [Google Scholar]
108. Bayani J, Paderova J, Murphy J, Rosen B, Zielenska M, Squire JA. Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer. Neoplasia. 2008;10:1057–1065. [PMC free article] [PubMed] [Google Scholar]
109. Perez JM, Grimm J, Josephson L, Weissleder R. Integrated nanosensors to determine levels and functional activity of human telomerase. Neoplasia. 2008;10:1066–1072. [PMC free article] [PubMed] [Google Scholar]
110. Allen CE, Du J, Jiang B, Huang Q, Yakovich AJ, Barnard JA. Transformation by oncogenic Ras expands the early genomic response to transforming growth factor β in intestinal epithelial cells. Neoplasia. 2008;10:1073–1082. [PMC free article] [PubMed] [Google Scholar]
111. Romer MU, Larsen L, Offenberg H, Brunner N, Lademann UA. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposideinduced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia. 2008;10:1083–1091. [PMC free article] [PubMed] [Google Scholar]
112. Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K. SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia. 2008;10:1092–1104. [PMC free article] [PubMed] [Google Scholar]
113. Das B, Antoon R, Tsuchida R, Lotfi S, Morozova O, Farhat W, Malkin D, Koren G, Yeger H, Baruchel S. Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth. Neoplasia. 2008;10:1105–1119. [PMC free article] [PubMed] [Google Scholar]
114. Glogowska A, Pyka J, Kehlen A, Los M, Perumal P, Weber E, Cheng SY, Hoang-Vu C, Klonisch T. The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells. Neoplasia. 2008;10:1120–1130. [PMC free article] [PubMed] [Google Scholar]
115. Lincz LF, Mudge LM, Scorgie FE, Sakoff JA, Hamilton CS, Seldon M. Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the β deletion variant. Neoplasia. 2008;10:1131–1137. [PMC free article] [PubMed] [Google Scholar]
116. Li Q, Feldman RA, Radhakrishnan VM, Carey S, Martinez JD. Hsf1 is required for the nuclear translocation of p53 tumor suppressor. Neoplasia. 2008;10:1138–1145. [PMC free article] [PubMed] [Google Scholar]
117. Mehta GU, Shively SB, Duong H, Tran MG, Moncrief TJ, Smith JH, Li J, Edwards NA, Lonser RR, Zhuang Z, et al. Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease. Neoplasia. 2008;10:1146–1153. [PMC free article] [PubMed] [Google Scholar]
118. Schmieder M, Wolf S, Danner B, Stoehr S, Juchems MS, Wuerl P, Henne-Bruns D, Knippschild U, Hasel C, Kramer K. p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia. 2008;10:1154–1162. [PMC free article] [PubMed] [Google Scholar]
119. Stasinopoulos I, Mori N, Bhujwalla ZM. The malignant phenotype of breast cancer cells is reduced by COX-2 silencing. Neoplasia. 2008;10:1162–1169. [PMC free article] [PubMed] [Google Scholar]
120. Ashkenazi R, Gentry SN, Jackson TL. Pathways to tumorigenesis—modeling mutation acquisition in stem cells and their progeny. Neoplasia. 2008;10:1170–1182. [PMC free article] [PubMed] [Google Scholar]
121. Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquère S, Ripoche H, Khabir A, Tsao TW, Bosq J, Lo KW, et al. Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to toll-like receptor 3-mediated apoptosis. Neoplasia. 2008;10:1183–1194. [PMC free article] [PubMed] [Google Scholar]
122. Menschikowski M, Hagelgans A, Kostka H, Eisenhofer G, Siegert G. Involvement of epigenetic mechanisms in the regulation of secretory phospholipase A2 expression in Jurkat leukemia cells. Neoplasia. 2008;10:1195–1203. [PMC free article] [PubMed] [Google Scholar]
123. Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia. 2008;10:1204–1212. [PMC free article] [PubMed] [Google Scholar]
124. Jones GN, Tep C, Towns WH, II, Mihai G, Tonks ID, Kay GF, Schmalbrock PM, Stemmer-Rachamimov AO, Yoon SO, Kirschner LS. Tissue-specific ablation of Prkar1a causes schwannomas by suppressing NF protein production. Neoplasia. 2008;10:1213–1221. [PMC free article] [PubMed] [Google Scholar]
125. Roschke AV, Glebov OK, Lababidi S, Gehlhaus KS, Weinstein JN, Kirsch IR. Chromosomal instability is associated with higher expression of genes implicated in EMT, cancer invasiveness and metastasis, and lower expression of genes involved in cell cycle checkpoints, DNA repair and chromatin maintenance. Neoplasia. 2008;10:1222–1230. [PMC free article] [PubMed] [Google Scholar]
126. Gallagher SJ, Thompson JF, Indsto J, Scurr LL, Lett M, Gao B, Dunleavey R, Mann GJ, Kefford RF, Rizos H. p16INK4a expression and absence of B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia. 2008;10:1231–1239. [PMC free article] [PubMed] [Google Scholar]
127. Corsino PE, Davis BJ, Nørgaard PH, Parker NNT, Law M, Dunn W, Law BK. Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. Neoplasia. 2008;10:1240–1252. [PMC free article] [PubMed] [Google Scholar]
128. Gorringe KL, Choong DYH, Williams LH, Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL, Campbell IG. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia. 2008;10:1253–1258. [PMC free article] [PubMed] [Google Scholar]
129. Landen CN, Kim T, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, et al. Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer. Neoplasia. 2008;10:1259–1267. [PMC free article] [PubMed] [Google Scholar]
130. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA. Chemotherapy induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia. 2008;10:1268–1274. [PMC free article] [PubMed] [Google Scholar]
131. Liu F, Chen Z, Wang J, Shao X, Cui Z, Yang C, Zhu Z, Xiong D. Overexpression of cell-surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia. 2008;10:1275–1284. [PMC free article] [PubMed] [Google Scholar]
132. Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia. 2008;10:1285–1294. [PMC free article] [PubMed] [Google Scholar]
133. Schneider A, Younis RH, Gutkind JS. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia. 2008;10:1295–1302. [PMC free article] [PubMed] [Google Scholar]
134. Elia U, Flescher E. PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate towards sarcoma cells. Neoplasia. 2008;10:1303–1313. [PMC free article] [PubMed] [Google Scholar]
135. Rehemtulla A. Neoplasia: the second decade. Neoplasia. 2008;10:1314–1324. [PMC free article] [PubMed] [Google Scholar]
136. Triplett AA, Montagna CM, Wagner K. A mammary-specific, longrange deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis. Neoplasia. 2008;10:1325–1334. [PMC free article] [PubMed] [Google Scholar]
137. Jiang W, Xiang C, Cazacu S, Brodie C, Mikkelsen T. Insulin-like growth factor binding protein 7 (IGFBP-7) mediates glioma cell growth and migration. Neoplasia. 2008;10:1335–1342. [PMC free article] [PubMed] [Google Scholar]
138. Michael LE, Westerman BA, Ermilov AN, Wang A, Ferris J, Liu J, Blom M, Ellison DW, Lohuizen MV, Dlugosz A. Bmi1 is required for Hedgehog-pathway driven medulloblastoma expansion. Neoplasia. 2008;10:1343–1349. [PMC free article] [PubMed] [Google Scholar]
139. Sprenger CCT, Drivdahl RH, Woodke LB, Eyman D, Reed MR, Carter WG, Plymate S. Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cells. Neoplasia. 2008;10:1350–1361. [PMC free article] [PubMed] [Google Scholar]
140. Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER, et al. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia. 2008;10:1362–1372. [PMC free article] [PubMed] [Google Scholar]
141. Calzolari F, Appolloni I, Tutucci E, Caviglia S, Terrile M, Corte G, Malatesta P. Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Neoplasia. 2008;10:1373–1382. [PMC free article] [PubMed] [Google Scholar]
142. Mathieu V, Neve ND, Mercier ML, Dewelle J, Gaussin J, Dehaux M, Kiss R, LeFranc F. Combining bevacizumab with temozolomide increases the anti-tumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008;10:1383–1392. [PMC free article] [PubMed] [Google Scholar]
143. Chen JY, Hung C, Huang K, Chen Y, Liu S, Chiang W, Chen H, Yen C, Wu Y, Ko J, et al. Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma. Neoplasia. 2008;10:1393–1401. [PMC free article] [PubMed] [Google Scholar]
144. Ogbomo H, Michaelis M, Klassert D, Doerr HW, Cinatl J. Resistance of cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia. 2008;10:1402–1410. [PMC free article] [PubMed] [Google Scholar]
145. Kim HK, Zhang H, Li H, Wu T, Swisher S, He D, Wu L, Xu J, Elmets CA, Athar M, et al. Slit2 inhibits the growth and metastasis of fibrosarcoma and squamous cell carcinoma. Neoplasia. 2008;10:1411–1420. [PMC free article] [PubMed] [Google Scholar]
146. Rowe A, Weiske J, Kramer TS, Huber O, Jackson P. Phorbol ester enhances KAI1 transcription by recruiting Tip60/Pontin complexes. Neoplasia. 2008;10:1421–1432. [PMC free article] [PubMed] [Google Scholar]
147. Grange C, Stefania L, Cavallo F, Camussi G, Bussolati B. Sca-1 identifies the tumor initiating cells in mammary tumors of BALB-NEUT transgenic mice. Neoplasia. 2008;10:1433–1443. [PMC free article] [PubMed] [Google Scholar]
148. Li Q, Mattingly RR. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. Neoplasia. 2008;10:1444–1458. [PMC free article] [PubMed] [Google Scholar]
149. Tilborg GAF, Mulder WJM, Schaft DKJ, Reutelingsperger CPM, Griffioen AW, Strijkers GJ, Nicolay K. Improved MR molecular imaging of tumor angiogenesis by avidin-induced clearance of non-bound bimodal liposomes. Neoplasia. 2008;10:1459–1469. [PMC free article] [PubMed] [Google Scholar]
150. Tamimi Y, Ekuere U, Laughton N, Milanovic A, Grundy P. WNT5A is regulated by PAX2 and may be involved in blastemal predominant Wilms tumorigenesis. Neoplasia. 2008;10:1470–1480. [PMC free article] [PubMed] [Google Scholar]
151. Tomassetti A, De Santis G, Castellano G, Miotti S, Mazzi M, Tomasoni D, Van Roy F, Carcangiu ML, Canevari S. Variant HNF1 modulates epithelial plasticity of normal and transformed ovary cells. Neoplasia. 2008;10:1481–1492. [PMC free article] [PubMed] [Google Scholar]
152. Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia. 2009;11:1–9. [PMC free article] [PubMed] [Google Scholar]
153. Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De Petro G, Pierotti MA, Zunino F, Borrello MG, Lanzi C. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and β-catenin nuclear translocation. Neoplasia. 2009;11:10–21. [PMC free article] [PubMed] [Google Scholar]
154. Lee SH, Lee SJ, Jung YS, Xu Y, Kang HS, Ha NC, Park BJ. Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function. Neoplasia. 2009;11:22–31. [PMC free article] [PubMed] [Google Scholar]
155. Hu XB, Feng F, Wang YC, Wang L, He F, Dou GR, Liang L, Zhang HW, Liang YM, Han H. Blockade of Notch signaling in tumor-bearing mice may lead to tumor regression, progression, or metastasis, depending on tumor cell types. Neoplasia. 2009;11:32–38. [PMC free article] [PubMed] [Google Scholar]
156. Haines BB, Bettano KA, Chenard M, Sevilla RS, Ware C, Angagaw MH, Winkelmann CT, Tong C, Reilly JF, Sur C, et al. A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models. Neoplasia. 2009;11:39–47. [PMC free article] [PubMed] [Google Scholar]
157. Savai R, Langheinrich AC, Schermuly RT, Pullamsetti SS, Dumitrascu R, Traupe H, Rau WS, Seeger W, Grimminger F, Banat GA. Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia. 2009;11:48–56. [PMC free article] [PubMed] [Google Scholar]
158. Zou M, Baitei EY, Alzahrani AS, Al-Mohanna F, Farid NR, Meyer B, Shi Y. Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors. Neoplasia. 2009;11:57–65. [PMC free article] [PubMed] [Google Scholar]
159. Wu Z, Cho H, Hampton GM, Theodorescu D. Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia. 2009;11:66–76. [PMC free article] [PubMed] [Google Scholar]
160. Kolesnikova TV, Kazarov AR, Lemieux ME, Lafleur MA, Kesari S, Kung AL, Hemler ME. Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. Neoplasia. 2009;11:77–86. [PMC free article] [PubMed] [Google Scholar]
161. Nosho K, Shima K, Kure S, Irahara N, Baba Y, Chen L, Kirkner GJ, Fuchs CS, Ogino S. JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia. 2009;11:87–95. [PMC free article] [PubMed] [Google Scholar]
162. Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia. 2009;11:96–101. [PMC free article] [PubMed] [Google Scholar]
163. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102–125. [PMC free article] [PubMed] [Google Scholar]
164. Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K. Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia. 2009;11:126–135. [PMC free article] [PubMed] [Google Scholar]
165. Toy EP, Azodi M, Folk NL, Zito CM, Zeiss CJ, Chambers SK. Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colonystimulating factor. Neoplasia. 2009;11:136–144. [PMC free article] [PubMed] [Google Scholar]
166. Grzelinski M, Steinberg F, Martens T, Czubayko F, Lamszus K, Aigner A. Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia. 2009;11:145–156. [PMC free article] [PubMed] [Google Scholar]
167. Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia. 2009;11:157–166. [PMC free article] [PubMed] [Google Scholar]
168. Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Möller P, Poppema S, Kroesen BJ, van den Berg A. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia. 2009;11:167–176. [PMC free article] [PubMed] [Google Scholar]
169. Halin S, Rudolfsson SH, Van Rooijen N, Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia. 2009;11:177–186. [PMC free article] [PubMed] [Google Scholar]
170. Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG, Neuwelt EA. Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia. 2009;11:187–195. [PMC free article] [PubMed] [Google Scholar]
171. Büchler P, Reber HA, Tomlinson JS, Hankinson O, Kallifatidis G, Friess H, Herr I, Hines OJ. Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia. 2009;11:196–206. [PMC free article] [PubMed] [Google Scholar]
172. Salvi A, Bongarzone I, Miccichè F, Arici B, Barlati S, De Petro G. Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells. Neoplasia. 2009;11:207–219. [PMC free article] [PubMed] [Google Scholar]
173. Baeten J, Haller J, Shih H, Ntziachristos V. In vivo investigation of breast cancer progression by use of an internal control. Neoplasia. 2009;11:220–227. [PMC free article] [PubMed] [Google Scholar]
174. Cai Z, Chen Q, Chen J, Lu Y, Xiao G, Wu Z, Zhou Q, Zhang J. Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia. 2009;11:228–236. [PMC free article] [PubMed] [Google Scholar]
175. Young MR, Ileva LV, Bernardo M, Riffle LA, Jones YL, Kim YS, Colburn NH, Choyke PL. Monitoring of tumor promotion and progression in a mouse model of inflammation-induced colon cancer with magnetic resonance colonography. Neoplasia. 2009;11:237–246. [PMC free article] [PubMed] [Google Scholar]
176. Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, O'Donoghue J, Ling CC, Humm JL, Zanzonico PB, et al. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia. 2009;11:247–259. [PMC free article] [PubMed] [Google Scholar]
177. Maire G, Yoshimoto M, Chilton-MacNeill S, Thorner PS, Zielenska M, Squire JA. Recurrent RECQL4 imbalance and increased gene expression levels are associated with structural chromosomal instability in sporadic osteosarcoma. Neoplasia. 2009;11:260–268. [PMC free article] [PubMed] [Google Scholar]
178. Tiziani S, Lopes V, Günther UL. Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia. 2009;11:269–276. [PMC free article] [PubMed] [Google Scholar]
179. Gaustad JV, Simonsen TG, Brurberg KG, Huuse EM, Rofstad EK. Blood supply in melanoma xenografts is governed by the morphology of the supplying arteries. Neoplasia. 2009;11:277–285. [PMC free article] [PubMed] [Google Scholar]
180. Marlin JW, Eaton A, Montano GT, Chang YW, Jakobi R. Elevated p21-activated kinase 2 activity results in anchorage-independent growth and resistance to anticancer drug-induced cell death. Neoplasia. 2009;11:286–297. [PMC free article] [PubMed] [Google Scholar]
181. Moschos C, Psallidas I, Kollintza A, Karabela S, Papapetropoulos A, Papiris S, Light RW, Roussos C, Stathopoulos GT, Kalomenidis I. The angiopoietin/Tie2 axis mediates malignant pleural effusion formation. Neoplasia. 2009;11:298–304. [PMC free article] [PubMed] [Google Scholar]
182. Castro P, Creighton CJ, Ozen M, Berel D, Mims MP, Ittmann M. Genomic profiling of prostate cancers from African American men. Neoplasia. 2009;11:305–312. [PMC free article] [PubMed] [Google Scholar]
183. Yang Y, Zhao Y, Liao W, Yang J, Wu L, Zheng Z, Yu Y, Zhou W, Li L, Feng J, et al. Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia. 2009;11:313–324. [PMC free article] [PubMed] [Google Scholar]
184. Chang VT, Cartwright PS, Bean SM, Palmer GM, Bentley RC, Ramanujam N. Quantitative physiology of the precancerous cervix in vivo through optical spectroscopy. Neoplasia. 2009;11:325–332. [PMC free article] [PubMed] [Google Scholar]
185. Walenkamp AM, Boer IG, Bestebroer J, Rozeveld D, Timmer-Bosscha H, Hemrika W, van Strijp JA, de Haas CJ. Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration. Neoplasia. 2009;11:333–344. [PMC free article] [PubMed] [Google Scholar]
186. Xu L, Chen Y, Song Q, Xu D, Wang Y, Ma D. PDCD5 interacts with Tip60 and functions as a cooperator in acetyltransferase activity and DNA damage-induced apoptosis. Neoplasia. 2009;11:345–354. [PMC free article] [PubMed] [Google Scholar]
187. van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia. 2009;11:355–364. [PMC free article] [PubMed] [Google Scholar]
188. Simon DP, Vadakkadath Meethal S, Wilson AC, Gallego MJ, Weinecke SL, Bruce E, Lyons PF, Haasl RJ, Bowen RL, Atwood CS. Activin receptor signaling regulates prostatic epithelial cell adhesion and viability. Neoplasia. 2009;11:365–376. [PMC free article] [PubMed] [Google Scholar]
189. Kislin KL, McDonough WS, Eschbacher JM, Armstrong BA, Berens ME. NHERF-1: modulator of glioblastoma cell migration and invasion. Neoplasia. 2009;11:377–387. [PMC free article] [PubMed] [Google Scholar]
190. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, et al. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia. 2009;11:388–396. [PMC free article] [PubMed] [Google Scholar]
191. Rodriguez R, Rubio R, Masip M, Catalina P, Nieto A, de la Cueva T, Arriero M, San Martin N, de la Cueva E, Balomenos D, et al. Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia. 2009;11:397–407. [PMC free article] [PubMed] [Google Scholar]
192. Asada M, Ebihara S, Yamanda S, Niu K, Okazaki T, Sora I, Arai H. Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation. Neoplasia. 2009;11:408–417. [PMC free article] [PubMed] [Google Scholar]
193. Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia. 2009;11:418–425. [PMC free article] [PubMed] [Google Scholar]
194. Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P, Thorner PS, Irwin MS, Kaplan DR, Baruchel S. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia. 2009;11:426–435. [PMC free article] [PubMed] [Google Scholar]
195. Jiang CC, Yang F, Thorne RF, Zhu BK, Hersey P, Zhang XD. Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia. 2009;11:436–447. [PMC free article] [PubMed] [Google Scholar]
196. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia. 2009;11:448–458. [PMC free article] [PubMed] [Google Scholar]
197. Leimgruber A, Berger C, Cortez-Retamozo V, Etzrodt M, Newton AP, Waterman P, Figueiredo JL, Kohler RH, Elpek N, Mempel TR, et al. Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia. 2009;11:459–468. [PMC free article] [PubMed] [Google Scholar]
198. Trompouki E, Tsagaratou A, Kosmidis SK, Dollé P, Qian J, Kontoyiannis DL, Cardoso WV, Mosialos G. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia. 2009;11:469–476. [PMC free article] [PubMed] [Google Scholar]
199. Nimmagadda S, Glunde K, Pomper MG, Bhujwalla ZM. Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells. Neoplasia. 2009;11:477–484. [PMC free article] [PubMed] [Google Scholar]
200. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, et al. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia. 2009;11:485–496. [PMC free article] [PubMed] [Google Scholar]
201. Erkan M, Reiser-Erkan C, Michalski CW, Deucker S, Sauliunaite D, Streit S, Esposito I, Friess H, Kleeff J. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia. 2009;11:497–508. [PMC free article] [PubMed] [Google Scholar]
202. Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, et al. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia. 2009;11:509–517. [PMC free article] [PubMed] [Google Scholar]
203. Huch M, Gros A, José A, González JR, Alemany R, Fillat C. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia. 2009;11:518–528. [PMC free article] [PubMed] [Google Scholar]
204. Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. Inflammatory cytokine tumor necrosis factor a confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia. 2009;11:529–541. [PMC free article] [PubMed] [Google Scholar]
205. Nitin N, Rosbach KJ, El-Naggar A, Williams M, Gillenwater A, Richards-Kortum RR. Optical molecular imaging of epidermal growth factor receptor expression to improve detection of oral neoplasia. Neoplasia. 2009;11:542–551. [PMC free article] [PubMed] [Google Scholar]
206. Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, Chen CS. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia. 2009;11:552–563. [PMC free article] [PubMed] [Google Scholar]
207. Hart KM, Bak SP, Alonso A, Berwin B. Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer. Neoplasia. 2009;11:564–573. [PMC free article] [PubMed] [Google Scholar]
208. Witney TH, Kettunen MI, Day SE, Hu DE, Neves AA, Gallagher FA, Fulton SM, Brindle KM. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia. 2009;11:574–582. [PMC free article] [PubMed] [Google Scholar]
209. Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nör JE. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia. 2009;11:583–593. [PMC free article] [PubMed] [Google Scholar]
210. Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, et al. Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia. 2009;11:594–604. [PMC free article] [PubMed] [Google Scholar]
211. Song J, Shih IM, Chan DW, Zhang Z. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia. 2009;11:605–614. [PMC free article] [PubMed] [Google Scholar]
212. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009;11:615–628. [PMC free article] [PubMed] [Google Scholar]
213. Peltola K, Hollmen M, Maula SM, Rainio E, Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen PJ, et al. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia. 2009;11:629–636. [PMC free article] [PubMed] [Google Scholar]
214. Réjiba S, Bigand C, Parmentier C, Hajri A. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMKGDEPTand TS/RR siRNA strategies. Neoplasia. 2009;11:637–650. [PMC free article] [PubMed] [Google Scholar]
215. Gassmann P, Haier J, Schlüter K, Domikowsky B, Wendel C, Wiesner U, Kubitza R, Engers R, Schneider SW, Homey B, et al. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia. 2009;11:651–661. [PMC free article] [PubMed] [Google Scholar]
216. Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, et al. Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves β(2)-integrin-mediated interaction. Neoplasia. 2009;11:662–671. [PMC free article] [PubMed] [Google Scholar]
217. Linnerth NM, Siwicky MD, Campbell CI, Watson KL, Petrik JJ, Whitsett JA, Moorehead RA. Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Neoplasia. 2009;11:672–682. [PMC free article] [PubMed] [Google Scholar]
218. Mao Z, Jiang Y, Liu X, Seluanov A, Gorbunova V. DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia. 2009;11:683–691. [PMC free article] [PubMed] [Google Scholar]
219. Kelavkar UP, Hutzley J, McHugh K, Allen KG, Parwani A. Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes. Neoplasia. 2009;11:692–699. [PMC free article] [PubMed] [Google Scholar]
220. Vladimirova V, Mikeska T, Waha A, Soerensen N, Xu J, Reynolds PC, Pietsch T. Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. Neoplasia. 2009;11:700–711. [PMC free article] [PubMed] [Google Scholar]
221. Nakata K, Ohuchida K, Nagai E, Hayashi A, Miyasaka Y, Kayashima T, Yu J, Aishima S, Oda Y, Mizumoto K, et al. LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. Neoplasia. 2009;11:712–719. [PMC free article] [PubMed] [Google Scholar]
222. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia. 2009;11:720–731. [PMC free article] [PubMed] [Google Scholar]
223. Faraone D, Aguzzi MS, Toietta G, Facchiano AM, Facchiano F, Magenta A, Martelli F, Truffa S, Cesareo E, Ribatti D, et al. Platelet-derived growth factor-receptor α strongly inhibits melanoma growth in vitro and in vivo. Neoplasia. 2009;11:732–742. [PMC free article] [PubMed] [Google Scholar]
224. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, Boeckers T, Debatin KM, Fulda S. Small-molecule XIAP inhibitors enhance γ-irradiation-induced apoptosis in glioblastoma. Neoplasia. 2009;11:743–752. [PMC free article] [PubMed] [Google Scholar]
225. Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM. Mdm2 deficiency suppresses MYCN-driven neuroblastoma tumorigenesis in vivo. Neoplasia. 2009;11:753–762. [PMC free article] [PubMed] [Google Scholar]
226. Tseng RC, Lee CC, Hsu HS, Tzao C, Wang YC. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia. 2009;11:763–770. [PMC free article] [PubMed] [Google Scholar]
227. Goon PK, Lip GY, Stonelake PS, Blann AD. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia. 2009;11:771–779. [PMC free article] [PubMed] [Google Scholar]
228. Heimburg-Molinaro J, Almogren A, Morey S, Glinskii OV, Roy R, Wilding GE, Cheng RP, Glinsky VV, Rittenhouse-Olson K. Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen. Neoplasia. 2009;11:780–792. [PMC free article] [PubMed] [Google Scholar]
229. Wang LC, Thomsen L, Sutherland R, Reddy CB, Tijono SM, Chen CJ, Angel CE, Dunbar PR, Ching LM. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404) Neoplasia. 2009;11:793–803. [PMC free article] [PubMed] [Google Scholar]
230. Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia. 2009;11:804–811. [PMC free article] [PubMed] [Google Scholar]
231. Hofmann M, McCormack E, Mujić M, Rossberg M, Bernd A, Bereiter-Hahn J, Gjertsen BT, Wiig H, Kippenberger S. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia. 2009;11:812–822. [PMC free article] [PubMed] [Google Scholar]
232. Kaul A, Maltese WA. Killing of cancer cells by the photoactivatable protein kinase C inhibitor, calphostin C, involves induction of endoplasmic reticulum stress. Neoplasia. 2009;11:823–834. [PMC free article] [PubMed] [Google Scholar]
233. Chen YW, Boyartchuk V, Lewis BC. Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia. 2009;11:835–845. [PMC free article] [PubMed] [Google Scholar]
234. Meeran SM, Katiyar N, Singh T, Katiyar SK. Loss of endogenous interleukin-12 activates survival signals in ultraviolet-exposed mouse skin and skin tumors. Neoplasia. 2009;11:846–855. [PMC free article] [PubMed] [Google Scholar]
235. Palmowski M, Peschke P, Huppert J, Hauff P, Reinhardt M, Maurer M, Karger CP, Scholz M, Semmler W, Huber PE, et al. Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions. Neoplasia. 2009;11:856–863. [PMC free article] [PubMed] [Google Scholar]
236. Lin Y, Buckhaults PJ, Lee JR, Xiong H, Farrell C, Podolsky RH, Schade RR, Dynan WS. Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia. 2009;11:864–873. [PMC free article] [PubMed] [Google Scholar]
237. Ferretti S, Allegrini PR, Becquet MM, McSheehy PM. Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia. 2009;11:874–881. [PMC free article] [PubMed] [Google Scholar]
238. Witte HT, Jeibmann A, Klämbt C, Paulus W. Modeling glioma growth and invasion in Drosophila melanogaster. Neoplasia. 2009;11:882–888. [PMC free article] [PubMed] [Google Scholar]
239. Vishwanath K, Yuan H, Barry WT, Dewhirst MW, Ramanujam N. Using optical spectroscopy to longitudinally monitor physiological changes within solid tumors. Neoplasia. 2009;11:889–900. [PMC free article] [PubMed] [Google Scholar]
240. Glinsky VV, Kiriakova G, Glinskii OV, Mossine VV, Mawhinney TP, Turk JR, Glinskii AB, Huxley VH, Price JE, Glinsky GV. Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia. 2009;11:901–909. [PMC free article] [PubMed] [Google Scholar]
241. Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia. 2009;11:910–920. [PMC free article] [PubMed] [Google Scholar]
242. Cohen B, Addadi Y, Sapoznik S, Meir G, Kalchenko V, Harmelin A, Ben-Dor S, Neeman M. Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75. Neoplasia. 2009;11:921–933. [PMC free article] [PubMed] [Google Scholar]
243. Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia. 2009;11:934–944. [PMC free article] [PubMed] [Google Scholar]
244. Jiang CC, Wroblewski D, Yang F, Hersey P, Zhang XD. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia. 2009;11:945–955. [PMC free article] [PubMed] [Google Scholar]
245. Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, et al. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia. 2009;11:956–963. [PMC free article] [PubMed] [Google Scholar]
246. Jiang R, Cabras G, Sheng W, Zeng Y, Ooka T. Synergism of BARF1 with Ras induces malignant transformation in primary primate epithelial cells and human nasopharyngeal epithelial cells. Neoplasia. 2009;11:964–973. [PMC free article] [PubMed] [Google Scholar]
247. Cosse JP, Ronvaux M, Ninane N, Raes MJ, Michiels C. Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia. 2009;11:976–986. [PMC free article] [PubMed] [Google Scholar]
248. Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C. Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia. 2009;11:987–1002. [PMC free article] [PubMed] [Google Scholar]
249. Neuwelt AJ, Wu YJ, Knap N, Losin M, Neuwelt EA, Pagel MA, Warmann S, Fuchs J, Czauderna P, Wozniak M. Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Neoplasia. 2009;11:1003–1011. [PMC free article] [PubMed] [Google Scholar]
250. Wang Q, Gao F, Wang T, Flagg T, Deng X. A nonhomologous end-joining pathway is required for protein phosphatase 2A promotion of DNA double-strand break repair. Neoplasia. 2009;11:1012–1021. [PMC free article] [PubMed] [Google Scholar]
251. Luker KE, Gupta M, Steele JM, Foerster BR, Luker GD. Imaging ligand-dependent activation of CXCR7. Neoplasia. 2009;11:1022–1035. [PMC free article] [PubMed] [Google Scholar]
252. Yan P, Qu Z, Ishikawa C, Mori N, Xiao G. Human T-cell leukemia virus type I-mediated repression of PDZ-LIM domain-containing protein 2 involves DNA methylation but independent of the viral oncoprotein tax. Neoplasia. 2009;11:1036–1041. [PMC free article] [PubMed] [Google Scholar]
253. Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, Perry D, O'Flaherty JT, Edwards IJ. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia. 2009;11:1042–1053. [PMC free article] [PubMed] [Google Scholar]
254. Blaheta RA, Powerski M, Hudak L, Juengel E, Jonas D, von Knethen A, Doerr HW, Cinatl J., Jr Tumor-endothelium cross talk blocks recruitment of neutrophils to endothelial cells: a novel mechanism of endothelial cell anergy. Neoplasia. 2009;11:1054–1063. [PMC free article] [PubMed] [Google Scholar]
255. Merighi S, Simioni C, Gessi S, Varani K, Mirandola P, Tabrizi MA, Baraldi PG, Borea PA. A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia. 2009;11:1064–1073. [PMC free article] [PubMed] [Google Scholar]
256. Meeh PF, Farrell CL, Croshaw R, Crimm H, Miller SK, Oroian D, Kowli S, Zhu J, Carver W, Wu W, et al. A gene expression classifier of nodepositive colorectal cancer. Neoplasia. 2009;11:1074–1083. [PMC free article] [PubMed] [Google Scholar]
257. Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia. 2009;11:1084–1092. [PMC free article] [PubMed] [Google Scholar]
258. Jung T, Castellana D, Klingbeil P, Hernández IC, Vitacolonna M, Orlicky DJ, Roffler SR, Brodt P, Zöller M. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia. 2009;11:1093–1105. [PMC free article] [PubMed] [Google Scholar]
259. Margheri F, Serratì S, Lapucci A, Anastasia C, Giusti B, Pucci M, Torre E, Bianchini F, Calorini L, Albini A, et al. Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice. Neoplasia. 2009;11:1106–1115. [PMC free article] [PubMed] [Google Scholar]
260. Oikonomou E, Makrodouli E, Evangelidou M, Joyce T, Probert L, Pintzas A. BRAFV600E efficient transformation and induction of MSI versus KRASG12V induction of senescence markers in human colon cancer cells. Neoplasia. 2009;11:1116–1131. [PMC free article] [PubMed] [Google Scholar]
261. Jajoo S, Mukherjea D, Watabe K, Ramkumar V. Adenosine A3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia. 2009;11:1132–1145. [PMC free article] [PubMed] [Google Scholar]
262. Samassekou O, Ntwari A, Hébert J, Yan J. Individual telomere lengths in chronic myeloid leukemia. Neoplasia. 2009;11:1146–1154. [PMC free article] [PubMed] [Google Scholar]
263. Cesca M, Frapolli R, Berndt A, Scarlato V, Richter P, Kosmehl H, D'Incalci M, Ryan A, Giavazzi R. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia. 2009;11:1155–1164. [PMC free article] [PubMed] [Google Scholar]
264. Backer J, Krivoshein A, Hamby C, Pizzonia J, Gilbert K, Ray Y, Brand H, Paton A, Paton J, Backer M. Chaperone-targeting cytotoxin and ER stress-inducing drug synergize to kill cancer cells. Neoplasia. 2009;11:1165–1173. [PMC free article] [PubMed] [Google Scholar]
265. Lung R, Tong J, Sung Y, Leung P, Ng D, Chau S, Chan A, Ng E, Lo K, To K. Modulation of LMP2A expression by a newly identified EBV-encoded microRNA miR-BART22. Neoplasia. 2009;11:1174–1184. [PMC free article] [PubMed] [Google Scholar]
266. Havaleshko D, Smith S, Jun C, Cheon S, Owens C, Lee J, Liotta L, Espina V, Wulfkuhle J, Petricoin E, et al. Comparison of global versus EGFR pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia. 2009;11:1185–1193. [PMC free article] [PubMed] [Google Scholar]
267. Smith L, Qutob O, Watson M, Beavis A, Potts D, Welham K, Garimella V, Lind M, Drew P, Cawkwell L. Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? Neoplasia. 2009;11:1194–1207. [PMC free article] [PubMed] [Google Scholar]
268. Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG. The EGFR responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia. 2009;11:1208–1215. [PMC free article] [PubMed] [Google Scholar]
269. Koreckij TD, Trauger RJ, Montgomery RB, Pitts TEM, Coleman I, Nguyen H, Reading C, Nelson P, Vessella R, Corey E. HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia. 2009;11:1216–1225. [PMC free article] [PubMed] [Google Scholar]
270. Zhu H, Miao Z-H, Huang M, Feng JM, Zhang Z, Lu J-J, Cai Y, Tong L, Xu Y, Qian X, et al. Naphthalimides induce G2 arrest via the ATM-activated Chk2-executed pathway in HCT116 cells. Neoplasia. 2009;11:1226–1234. [PMC free article] [PubMed] [Google Scholar]
271. Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, Varsos ZS, Roca H, Pienta KJ. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia. 2009;11:1235–1242. [PMC free article] [PubMed] [Google Scholar]
272. Rofstad EK, Gaustad J-V, Brurberg KG, Mathiesen B, Galappathi K, Simonsen TG. Radiocurability is associated with interstitial fluid pressure in human tumor xenografts. Neoplasia. 2009;11:1243–1251. [PMC free article] [PubMed] [Google Scholar]
273. Rehemtulla A. The war on cancer rages on. Neoplasia. 2009;11:1252–1263. [PMC free article] [PubMed] [Google Scholar]
274. Alphonso A, Alahari SK. Stromal cells and integrins: conforming to the needs of the tumor microenvironment. Neoplasia. 2009;11:1264–1271. [PMC free article] [PubMed] [Google Scholar]
275. Chen X, Lin C, Jia X, Zeng Y, Yao S, Lv Z, Qin D, Fang X, Lei Y, Lu C. Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in nude mice. Neoplasia. 2009;11:1272–1284. [PMC free article] [PubMed] [Google Scholar]
276. Koskimaki JE, Karagiannis ED, Rosca EV, Vesuna F, Winnard PT, Jr, Raman V, Bhujwalla ZM, Popel A. Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia. 2009;11:1285–1291. [PMC free article] [PubMed] [Google Scholar]
277. Navab R, Liu J, Seiden-Long I, Shih W, Li M, Bandarchi B, Chen Y, Lau D, Zu Y, Cescon D, et al. Co-overexpression of Met and HGF promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia. 2009;11:1292–1300. [PMC free article] [PubMed] [Google Scholar]
278. Romanska H, Tiziani S, Howe RC, Gunther U, Gulzar Z, Lalani E. NMR detects PI3k/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts. Neoplasia. 2009;11:1301–1308. [PMC free article] [PubMed] [Google Scholar]
279. Roca H, Varsos ZS, Pienta KJ. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression and cell survival in human prostate cancer PC3 cells. Neoplasia. 2009;11:1309–1317. [PMC free article] [PubMed] [Google Scholar]
280. Vesuna F, Lisok A, Kimble B, Raman V. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia. 2009;11:1318–1328. [PMC free article] [PubMed] [Google Scholar]
281. Silva SD, Mota LDC, Pinheiro DG, Torres C, de Carvalho AF, Cury PM, Nunes FD, Nishimoto IN, Soares FA, da Silva AMA, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia. 2009;11:1329–1339. [PMC free article] [PubMed] [Google Scholar]
282. Ju H, Lim B, Kim M, Kim YS, Kim WH, Ihm C, Noh S-M, Han DS, Yu H-J, Choi BY, et al. A regulatory polymorphism at position 09 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression. Neoplasia. 2009;11:1340–1347. [PMC free article] [PubMed] [Google Scholar]
283. Prakash J, Bansal R, Post E, de Jager-Krikken A, Lub-de Hooge MN, Poelstra K. Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-delta-12,14-prostaglandin-J2 in vivo. Neoplasia. 2009;11:1348–1358. [PMC free article] [PubMed] [Google Scholar]
284. Bram EE, Stark M, Raz S, Assaraf YG. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia. 2009;11:1359–1370. [PMC free article] [PubMed] [Google Scholar]
285. Huang C, Yang W, Chang S, Tai S, Tzeng C, Kao J, Wu K, Yang M. Regulation of membrane-type 4 matrix metalloproteinase (MT4-MMP) by SLUG contributes to hypoxia-mediated metastasis. Neoplasia. 2009;11:1371–1382. [PMC free article] [PubMed] [Google Scholar]
286. Ludwig N, Keller A, Heisel S, Leidinger P, Klein V, Rheinheimer S, Andres CU, Stephan B, Steudel WI, Graf NM, et al. Improving seroreactivity based detection of glioma. Neoplasia. 2009;11:1383–1389. [PMC free article] [PubMed] [Google Scholar]
287. Zillhardt M, Christensen JG, Lengyel E. An orally available small molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a pre-clinical model of ovarian cancer metastasis. Neoplasia. 2010;12:1–10. [PMC free article] [PubMed] [Google Scholar]
288. Silva A, Graves A, Guffei A, Ricca T, Mortara R, Jasiulionis M, Mai S. Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma. Neoplasia. 2010;12:11–19. [PMC free article] [PubMed] [Google Scholar]
289. Nakahara Y, Northcott PA, Li M, Kongkham PN, Smith C, Yan H, Croul S, Ra Y, Eberhart C, Huang A, et al. Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia. 2010;12:20–27. [PMC free article] [PubMed] [Google Scholar]
290. Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, Sparks R, Arvanitis A, Rogers J, Combs A, et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia. 2010;12:28–38. [PMC free article] [PubMed] [Google Scholar]
291. Lin L, Hutzen B, Li P, Ball S, Zuo M, De Angelis S, Foust E, Sobo M, Friedman L, Bhasin D, et al. A novel small molecule, LLL12 inhibits STAT3 phosphorylation and activities and exhibits potent growth suppressive activity in human cancer cells. Neoplasia. 2010;12:39–50. [PMC free article] [PubMed] [Google Scholar]
292. Tzuman Y, Sapoznik S, Granot D, Nevo N, Neeman M. Peritoneal adhesion and angiogenesis in ovarian carcinoma are inversely regulated by hyaluronan: the role of gonadotropins. Neoplasia. 2010;12:51–60. [PMC free article] [PubMed] [Google Scholar]
293. Liu Y, Laszlo C, Liu Y, Liu W, Chen X, Evans S, Wu S. Regulation of G1 arrest and apoptosis in hypoxia by PERK and GCN2-mediated eIF2α phosphorylation. Neoplasia. 2010;12:61–68. [PMC free article] [PubMed] [Google Scholar]
294. Lamoral-Theys D, Mercier M, Calve B, Rynkowski M, Bruyère C, Deacestecker C, Haibe-Kains B, Bontempi G, Dubois J, Lefranc F, et al. Long-term temozolomide treatment induces marked amino metabolism modifications and an increase. Neoplasia. 2010;12:69–79. [PMC free article] [PubMed] [Google Scholar]
295. Kahali S, Sarcar B, Fang B, Williams ES, Koomen JM, Tofilon PJ, Chinnaiyan P. Activation of the unfolded protein response (UPR) contributes towards the anti-tumor activity of the histone deacetylase (HDAC) inhibitor vorinostat. Neoplasia. 2010;12:80–86. [PMC free article] [PubMed] [Google Scholar]
296. Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Baars A, Giles RH, Witteveen EO, Voest EE. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia. 2010;12:87–94. [PMC free article] [PubMed] [Google Scholar]
297. Velmurugan B, Singh RP, Kaul N, Agarwal R, Agarwal C. Dietary feeding of grape seed extract prevents intestinal tumorigenesis in APCmin/+ mice. Neoplasia. 2010;12:95–102. [PMC free article] [PubMed] [Google Scholar]
298. Wang Q, Zhang W, Liu Q, Zhang X, Lv N, Ye L, Zhang X. A mutant of hepatitis B virus X protein (HBxΔ127) promotes cell growth via a positive feedback loop involving 5-lipoxygenase and fatty acid synthase. Neoplasia. 2010;12:103–115. [PMC free article] [PubMed] [Google Scholar]
299. Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia. 2010;12:116–127. [PMC free article] [PubMed] [Google Scholar]
300. Tang MK, Zhou HY, Yam JW, Wong AS. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia. 2010;12:128–138. [PMC free article] [PubMed] [Google Scholar]
301. Gong H, Kovar J, Little G, Chen H, Olive DM. In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific Affibody molecule labeled with a near-infrared fluorophore. Neoplasia. 2010;12:139–149. [PMC free article] [PubMed] [Google Scholar]
302. Li CH, Cheng YW, Liao PL, Kang JJ. Translocation of p53 to mitochondria is regulated by its lipid binding property to anionic phospholipids and it participates in cell death control. Neoplasia. 2010;12:150–160. [PMC free article] [PubMed] [Google Scholar]
303. Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, et al. Overexpression of Elafin in ovarian carcinoma is driven by genomic gains and activation of the NF-κB pathway and is associated with poor overall survival. Neoplasia. 2010;12:161–172. [PMC free article] [PubMed] [Google Scholar]
304. Rebhun RB, Cheng H, Gershenwald JE, Fan D, Fidler IJ, Langley RR. Constitutive expression of the α4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. Neoplasia. 2010;12:173–182. [PMC free article] [PubMed] [Google Scholar]
305. Gadji M, Fortin D, Tsanaclis AM, Garini Y, Katzir N, Wienburg Y, Yan J, Klewes L, Klonisch T, Drouin R, et al. Three-dimensional (3D) nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients. Neoplasia. 2010;12:183–191. [PMC free article] [PubMed] [Google Scholar]
306. Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depends on cell phenotype and the tumor microenvironment. Neoplasia. 2010;12:192–205. [PMC free article] [PubMed] [Google Scholar]
307. Langenberg MH, Witteveen PO, Lankheet NA, Roodhart JM, Rosing H, van den Heuvel IJ, Beijnen JH, Voest EE. Phase I study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors; safety, pharmacokinetics, pharmacodynamics analysis. Neoplasia. 2010;12:206–213. [PMC free article] [PubMed] [Google Scholar]
308. Zhao H, Ou-Yang F, Chen IF, Hou MF, Yuan SS, Chang HL, Lee YC, Plattner R, Waltz SE, Ho SM, et al. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. Neoplasia. 2010;12:214–223. [PMC free article] [PubMed] [Google Scholar]
309. Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, Nemenoff RA. Peroxisome proliferator-activated receptor-γ inhibits transformed growth of non-small cell lung cancer cells through selective suppression of snail. Neoplasia. 2010;12:224–234. [PMC free article] [PubMed] [Google Scholar]
310. Tonks ID, Mould AW, Schroder WA, Cotterill A, Hayward NK, Walker GJ, Kay GF. Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma. Neoplasia. 2010;12:235–243. [PMC free article] [PubMed] [Google Scholar]
311. Tennis MA, Van Scoyk M, Heasley LE, Vandervest K, Weiser-Evans M, Freeman S, Keith RL, Simpson P, Nemenoff RA, Winn RA. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9 dependent pathway that is blocked by secreted frizzled related protein 1. Neoplasia. 2010;12:244–253. [PMC free article] [PubMed] [Google Scholar]
312. Schneider M, Wortmann M, Mandal PK, Arpornchayanon W, Jannasch K, Alves F, Strieth S, Conrad M, Beck H. Absence of glutathione peroxidase 4 affects tumor angiogenesis through increased 12/15-lipoxygenase activity. Neoplasia. 2010;12:254–263. [PMC free article] [PubMed] [Google Scholar]
313. Tang TC, Man S, Lee CR, Xu P, Kerbel RS. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia. 2010;12:264–274. [PMC free article] [PubMed] [Google Scholar]
314. Campbell NE, Greenaway J, Henkin J, Moorehead RA, Petrik J. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia. 2010;12:275–283. [PMC free article] [PubMed] [Google Scholar]
315. Wang S, Huang J, He J, Wang A, Xu S, Huang SF, Xiao S. RPL41, a small ribosomal peptide deregulated in tumors, is essential for mitosis and centrosome integrity. Neoplasia. 2010;12:284–293. [PMC free article] [PubMed] [Google Scholar]
316. Mongiat M, Marastoni S, Ligresti G, Lorenzon E, Schiappacassi M, Perris R, Frustaci S, Colombatti A. The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment. Neoplasia. 2010;12:294–304. [PMC free article] [PubMed] [Google Scholar]
317. Burden-Gulley SM, Gates TJ, Burgoyne AM, Cutter JL, Lodowski DT, Robinson S, Sloan AE, Miller RH, Basilion JP, Brady-Kalnay SM. A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of PTPmu. Neoplasia. 2010;12:305–316. [PMC free article] [PubMed] [Google Scholar]
318. Lawrenson K, Grun B, Benjamin E, Jacobs IJ, Dafou D, Gayther SA. Senescent fibroblasts promote neoplastic transformation of ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. Neoplasia. 2010;12:317–325. [PMC free article] [PubMed] [Google Scholar]
319. Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, Schlösser A, Schmitt EK, Hallek M, Kreuzer KA. Small molecule inhibitors of Wnt/β-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia. 2010;12:326–335. [PMC free article] [PubMed] [Google Scholar]
320. Halin S, Rudolfsson SH, Doll JA, Crawford SE, Wikström P, Bergh A. Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is down-regulated by the prostate tumor microenvironment. Neoplasia. 2010;12:336–345. [PMC free article] [PubMed] [Google Scholar]
321. Fan S, Li Y, Yue P, Khuri FR, Sun SY. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP downregulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia. 2010;12:346–356. [PMC free article] [PubMed] [Google Scholar]
322. Watson RL, Spalding AC, Zielske SP, Morgan M, Kim AC, Bommer GT, Eldar-Finkelman H, Giordano T, Fearon ER, Hammer GD, et al. GSK3β and β-catenin modulate radiation cytotoxicity in pancreatic cancer. Neoplasia. 2010;12:357–365. [PMC free article] [PubMed] [Google Scholar]
323. Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG. The rGel/BLyS fusion toxin inhibits diffuse large B cell lymphoma growth in vitro and in vivo. Neoplasia. 2010;12:366–375. [PMC free article] [PubMed] [Google Scholar]
324. Lee PC, Kakadiya R, Su TL, Lee TC. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells. Neoplasia. 2010;12:376–387. [PMC free article] [PubMed] [Google Scholar]
325. Kerr BA, Miocinovic R, Smith AK, Klein EA, Byzova TV. Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model. Neoplasia. 2010;12:388–396. [PMC free article] [PubMed] [Google Scholar]
326. Tsunoda T, Takashima Y, Fujimoto T, Koyanagi M, Yoshida Y, Doi K, Tanaka Y, Kuroki M, Sasazuki T, Shirasawa S. 3D-specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. Neoplasia. 2010;12:397–404. [PMC free article] [PubMed] [Google Scholar]
327. Lafferty-Whyte K, Bilsland A, Hoare SF, Burns S, Zaffaroni N, Cairney CJ, Keith WN. TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression. Neoplasia. 2010;12:405–414. [PMC free article] [PubMed] [Google Scholar]
328. Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft via down-regulation of β-catenin-dependent signaling. Neoplasia. 2010;12:415–424. [PMC free article] [PubMed] [Google Scholar]
329. Hembruff SL, Jokar I, Yang L, Cheng N. Loss of TGF-β signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage dependent and independent mechanisms. Neoplasia. 2010;12:425–433. [PMC free article] [PubMed] [Google Scholar]
330. Arum CJ, Anderssen E, Viset T, Kodama Y, Lundgren S, Chen D, Zhao CM. Cancer immunoediting from immunosurveillance to tumour escape in microvillus-formed niche. A study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer. Neoplasia. 2010;12:434–442. [PMC free article] [PubMed] [Google Scholar]
331. van Houdt WJ, Hoogwater FJ, de Bruijn MT, Emmink BL, Nijkamp MW, Raats DA, van der Groep P, van Diest P, Borel Rinkes IH, Kranenburg O. Oncogenic KRAS desensitizes colorectal tumor cells to EGFR inhibition and activation. Neoplasia. 2010;12:443–452. [PMC free article] [PubMed] [Google Scholar]
332. Molina JR, Hayashi Y, Stephens C, Georgescu MM. Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia. 2010;12:453–463. [PMC free article] [PubMed] [Google Scholar]
333. Hail N, Jr, Chen P, Bushman LR. Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia. 2010;12:464–475. [PMC free article] [PubMed] [Google Scholar]
334. Broderick SR, Golas BJ, Pham D, Towe CW, Talbot SG, Kaufman A, Bains S, Huryn LA, Yonekawa Y, Carlson D, et al. SCCRO promotes glioma formation and malignant progression in mice. Neoplasia. 2010;12:476–484. [PMC free article] [PubMed] [Google Scholar]
335. Andl CD, McCowan KM, Allison GL, Rustgi AK. Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner. Neoplasia. 2010;12:485–498. [PMC free article] [PubMed] [Google Scholar]
336. Kadara H, Fujimoto J, Men T, Ye X, Lotan D, Lee JS, Lotan R. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia. 2010;12:499–505. [PMC free article] [PubMed] [Google Scholar]
337. Tysnes BB. Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia. 2010;12:506–515. [PMC free article] [PubMed] [Google Scholar]
338. Bassi DE, Zhang J, Cenna J, Litwin S, Cukierman E, Klein-Szanto AJ. Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis. Neoplasia. 2010;12:516–526. [PMC free article] [PubMed] [Google Scholar]
339. St Germain C, Niknejad N, Ma L, Garbuio K, Hai T, Dimitroulakos J. Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3. Neoplasia. 2010;12:527–538. [PMC free article] [PubMed] [Google Scholar]
340. Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A, De Cesaris P, Ziparo E, Del Bufalo D, Sitkovsky MV, et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 α Neoplasia. 2010;12:539–549. [PMC free article] [PubMed] [Google Scholar]
341. Meister S, Frey B, Lang VR, Gaipl US, Schett G, Schlötzer-Schrehardt U, Voll RE. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia. 2010;12:550–561. [PMC free article] [PubMed] [Google Scholar]
342. Defresne F, Bouzin C, Guilbaud C, Dieu M, Delaive E, Michiels C, Raes M, Feron O. Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker. Neoplasia. 2010;12:562–570. [PMC free article] [PubMed] [Google Scholar]
343. Fournier PG, Stresing V, Ebetino FH, Clézardin P. How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia. 2010;12:571–578. [PMC free article] [PubMed] [Google Scholar]
344. Dafou D, Grun B, Sinclair J, Lawrenson K, Benjamin EC, Hogdall E, Kruger-Kjaer S, Christensen L, Sowter HM, Al-Attar A, et al. Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia. 2010;12:579–589. [PMC free article] [PubMed] [Google Scholar]
345. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12:590–598. [PMC free article] [PubMed] [Google Scholar]
346. Aleshin A, Finn RS. SRC: a century of science brought to the clinic. Neoplasia. 2010;12:599–607. [PMC free article] [PubMed] [Google Scholar]
347. Kakkad SM, Solaiyappan M, O'Rourke B, Stasinopoulos I, Ackerstaff E, Raman V, Bhujwalla ZM, Glunde K. Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia. 2010;12:608–617. [PMC free article] [PubMed] [Google Scholar]
348. Hawcroft G, Loadman PM, Belluzzi A, Hull MA. Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells. Neoplasia. 2010;12:618–627. [PMC free article] [PubMed] [Google Scholar]
349. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, Schuler M, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia. 2010;12:628–636. [PMC free article] [PubMed] [Google Scholar]
350. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia. 2010;12:637–649. [PMC free article] [PubMed] [Google Scholar]
351. McClaine RJ, Marshall AM, Wagh PK, Waltz SE. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia. 2010;12:650–658. [PMC free article] [PubMed] [Google Scholar]
352. Ripka S, Riedel J, Neesse A, Griesmann H, Buchholz M, Ellenrieder V, Moeller F, Barth P, Gress TM, Michl P. Glutamate receptor GRIA3-target of CUX1 and mediator of tumor progression in pancreatic cancer. Neoplasia. 2010;12:659–667. [PMC free article] [PubMed] [Google Scholar]
353. Grinberg-Rashi H, Cytron S, Gelman-Kohan Z, Litmanovitch T, Avivi L. Replication timing aberrations and aneuploidy in peripheral blood lymphocytes of breast cancer patients. Neoplasia. 2010;12:668–674. [PMC free article] [PubMed] [Google Scholar]
354. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 2010;12:675–684. [PMC free article] [PubMed] [Google Scholar]
355. Brown JE, Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia. 2010;12:685–696. [PMC free article] [PubMed] [Google Scholar]
356. Tai JH, Tessier J, Ryan AJ, Hoffman L, Chen X, Lee TY. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat. Neoplasia. 2010;12:697–707. [PMC free article] [PubMed] [Google Scholar]
357. Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, Jordan RC. Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia. 2010;12:708–717. [PMC free article] [PubMed] [Google Scholar]
358. Toneff MJ, Du Z, Dong J, Huang J, Sinai P, Forman J, Hilsenbeck S, Schiff R, Huang S, Li Y. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia. 2010;12:718–726. [PMC free article] [PubMed] [Google Scholar]
359. Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, Gras T, Haibe-Kains B, Bontempi G, Decaestecker C, Ruysschaert JM, et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia. 2010;12:727–739. [PMC free article] [PubMed] [Google Scholar]
360. Hagmann W, Jesnowski R, Löhr JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010;12:740–747. [PMC free article] [PubMed] [Google Scholar]
361. Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, Bar-Eli M, Aldape KD, Fidler IJ. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia. 2010;12:748–754. [PMC free article] [PubMed] [Google Scholar]
362. Brauer R, Wang LC, Woon ST, Bridewell DJ, Henare K, Malinger D, Palmer BD, Vogel SN, Kieda C, Tijono SM, et al. Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action. Neoplasia. 2010;12:755–765. [PMC free article] [PubMed] [Google Scholar]
363. Zhou H, Liu Y, Cheung LH, Kim S, Zhang W, Mohamedali KA, Anand P, Hittelman WN, Aggarwal BB, Rosenblum MG. Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBα for specific inhibition of nuclear factor-κB activity. Neoplasia. 2010;12:766–777. [PMC free article] [PubMed] [Google Scholar]
364. Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA, Mazar AP. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia. 2010;12:778–788. [PMC free article] [PubMed] [Google Scholar]
365. Wakasaki T, Masuda M, Niiro H, Jabbarzadeh-Tabrizi S, Noda K, Taniyama T, Komune S, Akashi K. A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway. Neoplasia. 2010;12:789–796. [PMC free article] [PubMed] [Google Scholar]
366. Hotz B, Backer MV, Backer JM, Buhr HJ, Hotz HG. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer. Neoplasia. 2010;12:797–806. [PMC free article] [PubMed] [Google Scholar]
367. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia. 2010;12:807–817. [PMC free article] [PubMed] [Google Scholar]
368. Røe K, Seierstad T, Kristian A, Mikalsen LT, Mælandsmo GM, van der Kogel AJ, Ree AH, Olsen DR. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions. Neoplasia. 2010;12:818–825. [PMC free article] [PubMed] [Google Scholar]
369. Hu Y, Sun H, Owens RT, Gu Z, Wu J, Chen YQ, O'Flaherty JT, Edwards IJ. Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia. 2010;12:826–836. [PMC free article] [PubMed] [Google Scholar]
370. Sengupta S, Nandi S, Hindi ES, Wainwright DA, Han Y, Lesniak MS. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia. 2010;12:837–847. [PMC free article] [PubMed] [Google Scholar]
371. Li Y, Yue P, Deng X, Ueda T, Fukunaga R, Khuri FR, Sun SY. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia. 2010;12:848–855. [PMC free article] [PubMed] [Google Scholar]
372. Belaguli NS, Aftab M, Rigi M, Zhang M, Albo D, Berger DH. GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression. Neoplasia. 2010;12:856–865. [PMC free article] [PubMed] [Google Scholar]
373. Brioschi M, Fischer J, Cairoli R, Rossetti S, Pezzetti L, Nichelatti M, Turrini M, Corlazzoli F, Scarpati B, Morra E, et al. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. Neoplasia. 2010;12:866–876. [PMC free article] [PubMed] [Google Scholar]
374. Rantala J, Edgren H, Lehtinen L, Wolf M, Kleivi K, Vollan HKM, Aaltola A, Laasola P, Kilpinen S, Saviranta P, et al. Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. Neoplasia. 2010;12:877–888. [PMC free article] [PubMed] [Google Scholar]
375. Rofstad E, Mathiesen B. Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia. Neoplasia. 2010;12:889–898. [PMC free article] [PubMed] [Google Scholar]
376. Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L. Loss of STAT1 from mouse mammary epithelium results in an increased neu-induced tumor burden. Neoplasia. 2010;12:899–905. [PMC free article] [PubMed] [Google Scholar]
377. Harada Y, Suzuki H, Komiya A, Shibata S, Hasegawa M, Hayashi H, Ichikawa T, Yonemitsu Y. RIG-I helicase-independent pathway in Sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer. Neoplasia. 2010;12:906–914. [PMC free article] [PubMed] [Google Scholar]
378. Elo T, Valve EM, Seppänen JA, Vuorikoski HJ, Mäkelä S, Poutanen M, Kujala PM, Härkönen PL. Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice. Neoplasia. 2010;12:915–927. [PMC free article] [PubMed] [Google Scholar]
379. Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, Kerbel RS. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia. 2010;12:928–940. [PMC free article] [PubMed] [Google Scholar]
380. Witteveen PO, van der Mijn KJC, Los M, Kronemeijer RH, Groenewegen G, Voest EE. Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia. 2010;12:941–945. [PMC free article] [PubMed] [Google Scholar]
381. Rao G, Liu D, Xing M, Tauler J, Prinz RA, Xu X. Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation. Neoplasia. 2010;12:946–956. [PMC free article] [PubMed] [Google Scholar]
382. Hayashi Y, Molina J, Hamilton S, Georgescu M. NHERF1/EBP50 is a new marker in colorectal cancer. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]
383. Ericsson AC, Myles M, Davis W, Ma L, Michael L, Lillian M, Franklin C. Non-invasive detection of inflammation-associated colon cancer in a mouse model. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]
384. Rickman D, Chen Y, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, LaFargue CJ, Mertz KD, Setlur SR, et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]
385. Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankum KM, Miller LD, Liu ET, Mertani HC, Zhu T, et al. Trefoil factor-3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]
386. Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, Doerr HW, Wiese M, Kreuer J, Al-Abed Y, et al. Anti-cancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multi-drug resistant cancer cells. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]
387. Press JZ, Wurz K, Norquist B, Lee MK, Pennil C, Garcia R, Welcsh P, Goff BA, Swisher EM. Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]
388. Wu Z, Owens C, Chandra N, Popovic K, Conaway M, Theodorescu D. RalBP1 is necessary for metastasis of human cancer cell lines. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]
389. Bera S, Greiner S, Choudhury A, Dispenzieri A, Spitz D, Russell SJ, Goel A. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]
390. Fukunishi N, Katoh I, Tomimori Y, Tsukinoki K, Hata R, Nakao A, Ikawa Y, Kurata S. Induction of DeltaNp63 by the newly identified keratinocyte-specific TGF-β signaling pathway with Smad2 and IKKα in squamous cell carcinoma. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]
391. Maret D, Gruzglin E, Sadr M, Siu V, Shan W, Koch A, Seidah N, Maestro R, Colman D. Surface expression of precursor N-cadherin promotes tumor cell invasion. Neoplasia. 2010;12 [PMC free article] [PubMed] [Google Scholar]

Articles from Neoplasia (New York, N.Y.) are provided here courtesy of Neoplasia Press

-